A month after GSK’s win in Zantac cancer case, plaintiffs file dozens more suits

GSK now has dozens more Zantac lawsuits to contend with.

Plaintiffs on Wednesday filed 88 suits against GSK in Delaware court on behalf of more than 7,000 claimants who allege the popular ranitidine heartburn products caused a range of cancers. Pfizer, Boehringer Ingelheim and Sanofi, which owned Zantac rights at various points in time, were also named in the suit, in addition to Thermo Fisher’s Patheon Manufacturing Services.

GSK has been named in about 3,000 personal injury cases as well as class action suits. Plaintiffs in multidistrict litigation in Florida initially named 10 types of cancer in the suit, but later withdrew breast, kidney, colorectal, prostate and lung. Those cancers are still being pursued in state courts, GSK said last month. And on Friday, a Sanofi spokesperson attributed the recent surge in state court filings to plaintiffs who exited federal MDL, or whose alleged injuries have been dropped.

“The recent…
Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.


*